Journal
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Volume 131, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biocel.2020.105901
Keywords
RAS; Cysteine modification; Redox regulation
Categories
Funding
- Giovanni Armenise-Harvard Foundation
- Lung Cancer Research Foundation (LCRF)
Ask authors/readers for more resources
This review highlights the significance of oncogenic KRAS in human cancer and the lack of approved therapy to inhibit it. The focus is on the redox regulation of RAS and the potential of targeting C118 as a novel approach for KRAS inhibition.
Oncogenic KRAS is one of the most common drivers of human cancer. Despite intense research, no effective therapy to directly inhibit oncogenic KRAS has yet been approved and KRAS mutant tumors remain associated with a poor prognosis. This short review discusses the current knowledge of the redox regulation of RAS and examines the newest findings on cysteine 118 (C118) as a potential novel target for KRAS inhibition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
